Elisabetta Bonzano, Medical Director and Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared a post on X about a recent paper by Nils Gleim et al., published in Radiotherapy and Oncology:
“Neuroprotection in radiotherapy of brain metastases – a European pattern-of-care analysis by the ESTRO CNS Focus group
- The survey was completed by 234 ROs from 31 countries.
- WBRT is the preferred treatment modality over SRT for 4–5 BM for 18 % and for 6–10 BM for 53 % of ROs.
- HS-WBRT is generally offered by most ROs (85 %), only a minority apply the technique regularly (25 %), and prescription parameters vary considerably.
- Concomitant memantine is prescribed by 30 % of ROs.
- Boost treatments as part of WBRT are rarely performed on a regular basis (22 %)”
Title: Neuroprotection in radiotherapy of brain metastases – a European pattern-of-care analysis by the ESTRO CNS Focus group
Journal: Radiotherapy and Oncology
Authors: N. Gleim, A. Turcas, G. Minniti, A.L. Grosu, T. Kazda, M. Harat, S. Fernandez, M. Niyazi, N.H. Nicolay, C. Seidel
More posts featuring Elisabetta Bonzano on OncoDaily.
